DE69738352D1 - Anti-p53 spezifische einkettige-antikörperfragmente und deren verwendung - Google Patents

Anti-p53 spezifische einkettige-antikörperfragmente und deren verwendung

Info

Publication number
DE69738352D1
DE69738352D1 DE69738352T DE69738352T DE69738352D1 DE 69738352 D1 DE69738352 D1 DE 69738352D1 DE 69738352 T DE69738352 T DE 69738352T DE 69738352 T DE69738352 T DE 69738352T DE 69738352 D1 DE69738352 D1 DE 69738352D1
Authority
DE
Germany
Prior art keywords
antibody fragments
universal antibody
specific universal
concerns
restoring
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69738352T
Other languages
English (en)
Other versions
DE69738352T2 (de
Inventor
Laurent Bracco
Laurent Debussche
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharma SA
Original Assignee
Aventis Pharma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma SA filed Critical Aventis Pharma SA
Publication of DE69738352D1 publication Critical patent/DE69738352D1/de
Application granted granted Critical
Publication of DE69738352T2 publication Critical patent/DE69738352T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4746—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used p53
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE69738352T 1996-10-29 1997-10-27 Einkettige Anti-P53-Antikörperfragmente und Verwendungen Expired - Lifetime DE69738352T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9613176 1996-10-29
FR9613176A FR2755144B1 (fr) 1996-10-29 1996-10-29 Fragments d'anticorps a chaine unique anti-p53 et utilisation
PCT/FR1997/001921 WO1998018825A1 (fr) 1996-10-29 1997-10-27 Fragments d'anticorps a chaine unique anti-p53 et utilisations

Publications (2)

Publication Number Publication Date
DE69738352D1 true DE69738352D1 (de) 2008-01-17
DE69738352T2 DE69738352T2 (de) 2008-11-13

Family

ID=9497134

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69738352T Expired - Lifetime DE69738352T2 (de) 1996-10-29 1997-10-27 Einkettige Anti-P53-Antikörperfragmente und Verwendungen

Country Status (21)

Country Link
US (1) US6852509B1 (de)
EP (1) EP0941252B1 (de)
JP (1) JP4371178B2 (de)
KR (1) KR100874789B1 (de)
AT (1) ATE380198T1 (de)
AU (1) AU745530B2 (de)
BR (1) BR9712575A (de)
CA (1) CA2268865C (de)
CZ (1) CZ300526B6 (de)
DE (1) DE69738352T2 (de)
DK (1) DK0941252T3 (de)
ES (1) ES2297853T3 (de)
FR (1) FR2755144B1 (de)
HU (1) HU226330B1 (de)
IL (2) IL129476A0 (de)
NO (1) NO326452B1 (de)
PT (1) PT941252E (de)
SI (1) SI0941252T1 (de)
SK (1) SK286978B6 (de)
WO (1) WO1998018825A1 (de)
ZA (1) ZA979738B (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL121041A0 (en) 1997-06-09 1997-11-20 Yeda Res & Dev Immunogenic compositions for induction of anti-tumor immunity
US7199809B1 (en) 1998-10-19 2007-04-03 Symyx Technologies, Inc. Graphic design of combinatorial material libraries
AU769679B2 (en) * 1999-03-19 2004-01-29 St Vincent's Hospital Sydney Limited Anti-p53 antibodies
AUPP932199A0 (en) * 1999-03-19 1999-04-15 St Vincent's Hospital Sydney Limited Anti-p53 antibodies
DE19962583A1 (de) * 1999-12-23 2001-06-28 Mueller Hermelink Hans Konrad Antikörper gegen Plasmazellen
US6630584B1 (en) * 2000-03-16 2003-10-07 Ramot At Tel-Aviv University Ltd. Single chain antibody against mutant p53
US20080039409A1 (en) * 2003-12-24 2008-02-14 Locomogene, Inc. Method of Suppressing Cancer
JPWO2005061007A1 (ja) * 2003-12-24 2007-07-12 学校法人 聖マリアンナ医科大学 癌の抑制方法
GB0420771D0 (en) * 2004-09-17 2004-10-20 Randox Lab Ltd Antibody
WO2006100681A2 (en) * 2005-03-25 2006-09-28 Ramot At Tel Aviv University Ltd. Human synthetic single-chain antibodies directed against the common epitope of mutant p53 and their uses
WO2007028117A2 (en) * 2005-09-02 2007-03-08 New England Medical Center Hospitals, Inc. P8 as a marker for heart failure
JP7481726B2 (ja) * 2016-05-02 2024-05-13 プロセナ バイオサイエンシーズ リミテッド タウ認識抗体

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9224784D0 (en) * 1992-11-26 1993-01-13 Univ Dundee Cellular protein
FR2732348B1 (fr) * 1995-03-31 1997-04-30 Rhone Poulenc Rorer Sa Systeme d'expression conditionnel
FR2736915B1 (fr) * 1995-07-19 1997-08-22 Rhone Poulenc Rorer Sa Variants de la proteine p53 et utilisations therapeutiques

Also Published As

Publication number Publication date
NO326452B1 (no) 2008-12-08
SI0941252T1 (sl) 2008-04-30
ATE380198T1 (de) 2007-12-15
ZA979738B (en) 1998-05-22
HU226330B1 (en) 2008-09-29
KR100874789B1 (ko) 2008-12-18
AU745530B2 (en) 2002-03-21
CZ145599A3 (cs) 1999-08-11
SK55899A3 (en) 2000-06-12
IL129476A (en) 2010-05-17
JP4371178B2 (ja) 2009-11-25
AU4952097A (en) 1998-05-22
DK0941252T3 (da) 2008-03-31
CA2268865C (fr) 2011-01-04
WO1998018825A1 (fr) 1998-05-07
JP2001502553A (ja) 2001-02-27
ES2297853T3 (es) 2008-05-01
BR9712575A (pt) 1999-10-19
CA2268865A1 (fr) 1998-05-07
SK286978B6 (sk) 2009-08-06
FR2755144A1 (fr) 1998-04-30
NO991729L (no) 1999-04-13
US6852509B1 (en) 2005-02-08
HUP9904199A1 (hu) 2000-04-28
IL129476A0 (en) 2000-02-29
NO991729D0 (no) 1999-04-13
HUP9904199A3 (en) 2000-09-28
KR20000052845A (ko) 2000-08-25
FR2755144B1 (fr) 1998-11-27
EP0941252A1 (de) 1999-09-15
PT941252E (pt) 2008-03-07
DE69738352T2 (de) 2008-11-13
EP0941252B1 (de) 2007-12-05
CZ300526B6 (cs) 2009-06-10

Similar Documents

Publication Publication Date Title
EP1712623A3 (de) Selektion von Proteinen unter Verwendung von RNA-protein-fusionen
EP0804609A4 (de) NEUARTIGE AUF p53 ANSPRECHENDE GENE
GB2338237A (en) In vitro peptide or protein expression library
CA2282497A1 (en) In vitro peptide or protein expression library
ATE544776T1 (de) Chimäre dna-bindeproteine
BR9710968A (pt) Antìgenos de célula b humana; reagentes correlatos
ATE394484T1 (de) Smad 6 und dessen anwendungen
EP0921395A3 (de) Assays zur Bestimmung von Proteinfragmenten in biologischen Medien
DE69738352D1 (de) Anti-p53 spezifische einkettige-antikörperfragmente und deren verwendung
WO2000020587A3 (en) Cancer associated antigens and uses therefor
AU3477295A (en) Modified proteins
EP1012603A4 (de) Funktionelle fragmente des hiv-1 vpr proteins and eine methode zu seiner anwendung
WO2002012541A3 (en) Novel motor proteins and methods for their use
WO2001096593A3 (en) Novel motor proteins and methods for their use
NZ512332A (en) Potassium channel interactors and uses therefor
ES2152976T3 (es) Proteina crp mutante, procedimientos y medios para su fabricacion y su utilizacion.
EP0843006A3 (de) Rekombinante prostataspezifische Antigen-Vektoren und diese verwendende Assays
WO2001021794A3 (en) Smad associating polypeptides
WO2001098314A3 (en) Novel motor proteins and methods for their use
WO1999002564A3 (de) Ancrod spezifische monoklonale antikörper, antikörperfragmente, deren mischungen oder derivate und deren verwendung
MX9701904A (es) Proteinas de enlace de pka novedosas y usos de las mismas.
WO2000020586A3 (en) Renal cancer associated antigens and uses therefor
WO1999047668A3 (de) Für tumorsuppressorproteine kodierende nukleinsäure, tumorsuppressorproteine, verfahren zu deren herstellung, antikörper gegen tumorsuppressorproteine und verwendung dieser gegenstände

Legal Events

Date Code Title Description
8364 No opposition during term of opposition